The case for regeneration over slowing decline
Novartis’ President of Biomedical Research, Fiona Marshall, on what it would take for big pharma to go all in on longevity. When the person who runs research for one of the world’s largest drug companies turns up at a longevity meeting, people notice. Fiona Marshall oversees around 5,500 scientists
<p>Novartis’ President of Biomedical Research, Fiona Marshall, on what it would take for big pharma to go all in on longevity. When the person who runs research for one of the world’s largest drug companies turns up at a longevity meeting, people notice. Fiona Marshall oversees around 5,500 scientists </p>